SCHEMBL4267045

SCHEMBL4267045

CC(Oc1ccc2cc(-c3csc(-c4ccccc4)n3)ccc2c1)c1nnn[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25A P30304 1/20 0.49
CDC25B P30305 1/20 0.49
CDC25C P30307 1/20 0.49
DUSP3 P51452 1/20 0.49
SMN1; SMN2 Q16637 8/20 0.47
MAPT P10636 6/20 0.47
RAB9A P51151 6/20 0.47
NPC1 O15118 5/20 0.47
KDM4E B2RXH2 4/20 0.47
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
POLB P06746 1/20 0.44
GAA P10253 1/20 0.44
PKM P14618 1/20 0.44
HPGD P15428 1/20 0.44
ALOX12 P18054 1/20 0.44
HTT P42858 2/20 0.43
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4265820 0.78 CDC25A (0.53) CDC25ACDC25BCDC25CDUSP3SMN1; SMN2
SCHEMBL4267047 0.76 CDC25A (0.51) CDC25ACDC25BCDC25CDUSP3ATP4A
SCHEMBL4279335 0.76 MAPT (0.74) CDC25ACDC25BCDC25CDUSP3SMN1; SMN2
SCHEMBL14531237 0.72 CDC25A (0.69) CDC25ACDC25BCDC25CDUSP3SMN1; SMN2
SCHEMBL4269672 0.72 PPARG (0.63) CDC25ACDC25BCDC25CDUSP3
SCHEMBL4271656 0.71 CDC25A (0.52) CDC25ACDC25BCDC25CDUSP3SMN1; SMN2
SCHEMBL13545609 0.71 SREBF2 (0.57) SMN1; SMN2MAPTRAB9ANPC1KDM4E
SCHEMBL3597116 0.71 SREBF2 (0.57) SMN1; SMN2MAPTRAB9ANPC1KDM4E
SCHEMBL10660139 0.70 SREBF2 (0.60) SMN1; SMN2MAPTRAB9ANPC1KDM4E
SCHEMBL13545640 0.70 CYP19A1 (0.57) SMN1; SMN2MAPTRAB9ANPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605172-B2 Thiazolo-naphthyl acids WYETH (US) 2009-10-20 US claimed
US-20060052420-A1 Plasminogen activator inhibitor-1 (PAI-1) modulators; 3-phenyl-2-{[6-(2-phenyl-1,3-thiazol-4-yl)-2-naphthyl]oxy}propanoic acid; thrombosis; cardiovascular disease WYETH (US) 2006-03-09 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052420-A1 Plasminogen activator inhibitor-1 (PAI-1) modulators; 3-phenyl-2-{[6-(2-phenyl-1,3-thiazol-4-yl)-2-naphthyl]oxy}propanoic acid; thrombosis; cardiovascular disease SERPINE1, PLAT, SERPINC1 CDC25A 2671/4885CDC25B 3732/4885CDC25C 3520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.